The arginase inhibitor, CB-115 has shown therapeutic efficacy in multiple murine tumors models, including the 4T1 model of breast cancer, by reducing the numbers of tumor-infiltrating myeloid cells and encouraging anti-tumor CD8+ T and NK cell responses [66]. Here, CD8A is linked to breast carcinoma.